Evidence quality 4.5/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 4/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
● your factors — click this risk ▾ to reveal
- Your factors
≈ As likely as
Perceived
Cardiovascular disease is widely understood to be the leading cause of death in women globally, but the specific role of menopause as a risk accelerant is not well understood by most women. Cultural attention to breast cancer — a statistically less common outcome — has displaced awareness of the cardiovascular risk profile that menopause alters. Women in their late 40s and early 50s often do not know that their CVD risk doubles in the decade following their final menstrual period, or that the transition represents a meaningful window for preventive intervention. The asymmetry is reinforced by clinical practice: menopause consultations have historically focused on symptom management (vasomotor, sleep, genitourinary) rather than cardiovascular risk stratification.
Source: editorial intuition, not polled
Actual
33 in 100 women globally will develop cardiovascular disease during their lifetime (from age 40)
women from age 40 (lifetime CHD risk, Framingham / Lloyd-Jones 1999; menopause-timing modifiers from Lancet Public Health 2019 pooled IPD and the EHJ 2021 consensus document)
Show derivation
The native rate (33/100 ≈ 1 in 3) is the lifetime risk of coronary heart disease from age 40 reported by Lloyd-Jones et al. (Lancet 1999, Framingham): 31.7% (95% CI 29.2–34.2) for women. This is the figure that gives the familiar "one in three women" headline. Menopause timing modifies this baseline: the Lancet Public Health 2019 pooled IPD analysis (15 studies, 301,438 women) found premature menopause (<40) carried a hazard ratio of 1.55 (95% CI 1.38–1.73) for first non-fatal CVD versus menopause at 50–51, rising to 1.88 before age 60. The EHJ 2021 consensus document adds a ~3% increase in CVD risk per year of earlier menopause and notes the menopause-associated rise in CVD risk cannot be cleanly separated from chronological ageing — so this entry treats menopause as a timing-dependent risk modifier, not a fully aging-independent doubling. The 1-in-3 lifetime figure is US/Framingham-derived for CHD specifically; the broader "cardiovascular disease" umbrella and global/regional estimates vary, which the uncertainty band and caveats reflect. Low (0.28): the lower CI / favourable risk-factor and regional profiles (e.g. East Asian women with lower CVD burden). High (0.40): higher-burden profiles (e.g. Eastern European / Central Asian women with high hypertension and smoking prevalence, and broader all-CVD rather than CHD-only counts).
Caveats: The headline "1 in 3 from age 40" is the lifetime risk of coronary heart disease…
The headline "1 in 3 from age 40" is the lifetime risk of coronary heart disease specifically, from the Framingham cohort (Lloyd-Jones 1999, 31.7% for women); it is US-derived and CHD-specific, not a global all-CVD figure, so global and regional estimates differ. The broader "cardiovascular disease" umbrella (adding stroke, peripheral artery disease, and heart failure) and fatal-CHD-only counts give different numbers. The menopause-timing risk is a relative-risk increase, not an absolute incidence: in the Lancet PH 2019 pooled data premature menopause (<40) carried HR 1.55 for a first non-fatal CVD event (1.88 before age 60), and the EHJ 2021 consensus reports ~3% added CVD risk per year of earlier menopause — but that same consensus stresses the menopause-related rise cannot be cleanly separated from chronological ageing, so the "acceleration" should not be read as a fully aging-independent doubling. If a woman's absolute CHD risk in her 40s is low, a relative increase still leaves the absolute level low. The MHT window-of-opportunity evidence is clinically relevant but not embedded in the native probability; it belongs in a clinical discussion, not a population baseline. Regional variation is substantial — Japanese and Korean women have lower CVD lifetime risk and Eastern European / Central Asian women higher — reflecting different hypertension and smoking profiles, which the uncertainty band approximates.
Related risks
Other risks on similar themes — for exploring related fears.
Inheriting AUD risk
If a parent had alcohol use disorder, what are the odds you'll develop alcohol use disorder yourself?
Major depression
What are the odds of experiencing a major depressive episode in your lifetime?
Pick challenger
Cardiovascular disease is the leading cause of death in women globally, and in the US it kills more women each year than all cancers combined — yet the specific role of menopause as a risk accelerant is poorly understood by most women and inconsistently addressed in clinical practice. The Framingham Heart Study’s lifetime-risk analysis (Lloyd-Jones et al., Lancet 1999) put the lifetime risk of coronary heart disease from age 40 at 31.7% for women — about one in three. Menopause timing modifies that baseline: a 2019 Lancet Public Health pooled analysis of 15 studies covering 301,438 women found that women with premature menopause (before age 40) had a hazard ratio of 1.55 (95% CI 1.38–1.73) for a first non-fatal cardiovascular event compared with menopause at 50–51, with the excess larger before age 60 (HR 1.88). A European consensus document (Maas et al., European Heart Journal 2021) reports a roughly 3% rise in CVD risk per year of earlier menopause, while cautioning that the menopause-related increase in cardiovascular risk cannot be cleanly separated from chronological ageing.
The mechanism is estrogen-related. Estrogen has direct beneficial effects on vascular endothelium: it promotes vasodilation, reduces LDL cholesterol, and suppresses inflammatory markers. As estrogen levels decline through perimenopause and fall sharply after the final menstrual period, these protective effects diminish. The result is a measurable shift in vascular risk profile that occurs over a 5–10 year window around menopause, leaving a woman’s cardiovascular risk trajectory substantially steeper than it would have been had estrogen remained at premenopausal levels. The timing of menopause modifies the magnitude: in the Lancet Public Health pooled data, women who experienced premature menopause (before 40) carried roughly 1.5 times the cardiovascular-event risk of women with menopause at 50–51 overall, and close to 1.9 times before age 60 — and the European consensus document notes that women with premature ovarian insufficiency have a shorter life expectancy from cardiovascular disease and osteoporosis.
The clinical evidence on menopausal hormone therapy (MHT) adds an important nuance: a window-of-opportunity effect has been described. The European Heart Journal consensus document reports that “early initiation of MHT after menopause has the greatest benefit for cardiovascular health” and that women starting MHT below age 60 or within 10 years of menopause onset showed a significant reduction (>30%) in myocardial infarction or cardiac deaths. The earlier era of cardiovascular MHT concerns derived primarily from the Women’s Health Initiative, which enrolled older postmenopausal women initiating therapy more than a decade after menopause. The menopause-CVD relationship is therefore not only about risk magnitude but also about timing of intervention — a distinction that matters practically for how women and their clinicians approach the transition.
Related tidbits
About 1 in 3 women globally develops cardiovascular disease in her lifetime, and coronary incidence roughly doubles in the decade after menopause. Breast cancer draws more attention, yet heart disease kills far more women.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
3/4 sources independently verified verbatim against the cited source
-
[1] European Heart Journal (European Society of Cardiology) — Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists Verified
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists- Statistic
Each year of early menopause is associated with a ~3% increased risk of CVD; women with premature ovarian insufficiency have shorter life expectancy due to CVD; the CVD-risk increase at menopause cannot be cleanly distinguished from ageing; MHT initiated below age 60 or within 10 years of menopause onset was associated with a >30% reduction in MI or cardiac deaths (window-of-opportunity effect)- Excerpt
“"Each year of early menopause was associated with a 3% increased risk of CVD. Women with premature ovarian insufficiency (POI), defined as the loss of ovarian function before the age of 40, have a shorter life expectancy than women with a late menopause due to CVD and osteoporosis. While CVD risk increases with the menopause, this cannot be distinguished from ageing. Lower oestrogen levels after menopause are related to altered vascular function, enhanced inflammation, and up-regulation of other hormonal systems." "Women initiating MHT treatment below 60 years of age or within 10 years of onset of menopause showed a significant reduction (>30%) of MI or cardiac deaths." ”
- Source data from
- 2021-03-07
- Accessed
- 2026-06-30
- Verification
- Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
- Calculation
- Maas et al. (2021), European Heart Journal 42(10):967–984 — a consensus document from European cardiologists, gynaecologists, and endocrinologists (formally approved by the ESC Clinical Practice Guidelines Committee, but not the 2021 ESC CVD-prevention guideline itself). Used here for the menopause-specific risk modifiers: the 3%-per-year early-menopause gradient, premature ovarian insufficiency, and the estrogen-vascular mechanism. The same document also describes a menopausal-hormone-therapy (MHT) "window of opportunity": women initiating MHT below age 60 or within 10 years of menopause onset showed a significant (>30%) reduction in MI or cardiac deaths, which anchors the MHT paragraph in the body text. Note the document explicitly cautions that the menopause-associated CVD-risk rise cannot be cleanly separated from chronological ageing — the entry reflects this caveat rather than claiming a fully aging-independent effect.
-
[2] The Lancet Public Health — Age at natural menopause and risk of cardiovascular disease: pooled individual participant data from 15 observational studies
Age at natural menopause and risk of cardiovascular disease: pooled individual participant data from 15 observational studies- Statistic
Premature menopause (<40) associated with HR 1.55 (95% CI 1.38–1.73) for first non-fatal CVD vs menopause at 50–51; the excess is larger before age 60 (HR 1.88, 1.62–2.20). Pooled IPD, 301,438 women, 15 studies.- Excerpt
“"Compared with women who had menopause at age 50-51 years, the risk of cardiovascular disease was higher in women who had premature menopause (age <40 years; HR 1·55, 95% CI 1·38-1·73; p<0·0001), early menopause (age 40-44 years; 1·30, 1·22-1·39; p<0·0001), and relatively early menopause (age 45-49 years; 1·12, 1·07-1·18; p<0·0001). The associations persisted in never smokers, and were strongest before age 60 years for women with premature menopause (HR 1·88, 1·62-2·20; p<0·0001) and early menopause (1·40, 1·27-1·54; p<0·0001), but were attenuated at age 60-69 years, with no significant association observed at age 70 years and older." ”
- Source data from
- 2019-11-01
- Accessed
- 2026-06-30 · archived copy
- Calculation
- Zhu et al. (2019) Lancet Public Health — pooled IPD, 15 studies, 301,438 women (12,962 first non-fatal CVD events; 9,369 CHD; 4,338 stroke). The largest individual-participant dataset quantifying the menopause-timing–CVD relationship. The reported risk is for first non-fatal cardiovascular disease (a composite), not a separate CHD hazard ratio; premature menopause (<40) carries HR 1·55 overall and 1·88 before age 60. These figures support the `personal_factor_multipliers` for premature/surgical menopause used in this entry.
-
[3] The Lancet — Lifetime risk of developing coronary heart disease Verified
Lifetime risk of developing coronary heart diseaseSee all 2 Likelier entries citing this source →
- Statistic
Lifetime risk of coronary heart disease at age 40 is 31.7% (95% CI 29.2–34.2) for women and 48.6% for men — i.e. about one in three women. Framingham Heart Study, 7,733 participants.- Excerpt
“"Lifetime risk of CHD after 40 years of age was 48·6% (95% CI 45·8–51·3) for men and 31·7% (29·2–34·2) for women. At 70 years of age the remaining lifetime risk was 34·9% for men and 24·2% for women. Interpretation: Lifetime risk at age 40 years is one in two for men and one in three for women." ”
- Source data from
- 1999-01-09
- Accessed
- 2026-06-30 · archived copy
- Verification
- Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
- Calculation
- Lloyd-Jones, Larson, Beiser & Levy (1999), Lancet 353(9147):89–92 — Framingham Heart Study lifetime-risk analysis (n=7,733, CHD-free at baseline). This is the original source of the "one in three women from age 40" lifetime coronary-heart-disease figure that anchors this entry's native rate. Note the headline figure is for coronary heart disease specifically (not the full CVD umbrella) and is US/Framingham-derived; the entry's caveats flag that broader-CVD and global figures differ.
-
[4] American Heart Association / Go Red for Women — The Facts about Women and Heart Disease Verified
The Facts about Women and Heart Disease- Statistic
Cardiovascular disease kills more US women each year than all forms of cancer combined; only 44% of women recognize CVD as their greatest health threat- Excerpt
“"Cardiovascular disease kills more women than all forms of cancer combined and yet only 44% of women recognize that cardiovascular disease is their greatest health threat." ”
- Source data from
- 2024-01-01
- Accessed
- 2026-07-03 · archived copy
- Verification
- Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
- Calculation
- American Heart Association's Go Red for Women campaign facts page. Used here to source the entry's opening framing claim that cardiovascular disease kills more US women annually than all cancers combined, which motivates the "underrated" myth framing alongside the menopause-specific timing evidence from Maas et al. and Zhu et al. This is an all-cause CVD statistic, not menopause-specific.
- Independence
- Independent of the Framingham (Lloyd-Jones 1999), Lancet Public Health (Zhu 2019), and EHJ consensus (Maas 2021) sources — an AHA public-health communications source used solely for the all-cause CVD-vs-cancer mortality comparison in US women, not for any menopause-timing figure.